Alector reports Q4 net loss $41.4M; cash runway extended to 2026 after $75M equity offering

Alector, Inc.

2023-FY EPS reported -$1.56 revenue$97,100,000

Q4 net loss $41.4M ($0.49/sh) vs $52.4M ($0.63) YoY; FY net loss $130.4M ($1.56) vs $133.3M ($1.62).
Cash $548.9M at Dec 31; pro forma $620M after Jan 2024 equity offering, providing runway through 2026.
INVOKE-2 Phase 2 enrollment completed (381 pts); data due Q4 2024. Latozinemab granted FDA Breakthrough Therapy for FTD-GRN.
First patient dosed in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early AD in Feb 2024.
2024 guidance: collaboration revenue $60-70M, R&D $210-230M, G&A $60-70M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alector, Inc. reported financial results for the quarter ended December 31, 2023.

Period: the quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 27, 2024, Alector, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-021133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.